CytomX Therapeutics (CTMX) News Today $2.32 +0.21 (+9.95%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.35 +0.03 (+1.08%) As of 06/20/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Congress Park Capital LLC Cuts Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX)Congress Park Capital LLC reduced its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 30.2% in the first quarter, according to its most recent filing with the SEC. The fund owned 673,686 shares of the biotechnology company's stock after selling 290,904 shares during theJune 20 at 7:37 AM | marketbeat.comTwo Sigma Investments LP Cuts Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)Two Sigma Investments LP decreased its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 32.0% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 320,767 shares of the biotechnology company's stock after selling 150,701 shareJune 11, 2025 | marketbeat.comShort Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Grows By 82.0%CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) was the target of a large increase in short interest in May. As of May 15th, there was short interest totalling 17,730,000 shares, an increase of 82.0% from the April 30th total of 9,740,000 shares. Approximately 24.4% of the company's stock are sold short. Based on an average daily trading volume, of 5,060,000 shares, the short-interest ratio is currently 3.5 days.June 1, 2025 | marketbeat.comMillennium Management LLC Grows Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX)Millennium Management LLC raised its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 25.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,221,012 shares of the biotechnology comJune 1, 2025 | marketbeat.comTidal Investments LLC Buys 136,528 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)Tidal Investments LLC boosted its holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 55.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 382,529 shares of the biotechnology compaMay 31, 2025 | marketbeat.comCytomX Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comFormidable Asset Management LLC Grows Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)Formidable Asset Management LLC lifted its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 55.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 382,529 shares of the biotechnology cMay 27, 2025 | marketbeat.comPoint72 Asset Management L.P. Invests $2.73 Million in CytomX Therapeutics, Inc. (NASDAQ:CTMX)Point72 Asset Management L.P. bought a new position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,650,000 shares of theMay 23, 2025 | marketbeat.comCytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)May 20, 2025 | benzinga.comTang Capital Management LLC Sells 500,000 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)Tang Capital Management LLC lowered its position in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 6.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,311,760 shares of the biMay 20, 2025 | marketbeat.comEquities Analysts Set Expectations for CTMX Q2 EarningsCytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Equities researchers at HC Wainwright reduced their Q2 2025 earnings estimates for CytomX Therapeutics in a research report issued on Thursday, May 15th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will earn $0May 20, 2025 | marketbeat.comCytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic MelanomaMay 19, 2025 | globenewswire.comProsight Management LP Boosts Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)Prosight Management LP boosted its position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 29.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,905,000 shares of the biotechnology companMay 17, 2025 | marketbeat.comQ2 EPS Estimates for CytomX Therapeutics Cut by WedbushCytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Research analysts at Wedbush decreased their Q2 2025 earnings estimates for CytomX Therapeutics in a research report issued on Monday, May 12th. Wedbush analyst R. Driscoll now forecasts that the biotechnology company will post earnings of (May 16, 2025 | marketbeat.comBarclays Keeps Their Buy Rating on CytomX Therapeutics (CTMX)May 15, 2025 | theglobeandmail.comCytomX upgraded at H.C. Wainwright on trial data for cancer drugMay 15, 2025 | msn.comHC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX)May 15, 2025 | msn.comAfter pivots and layoffs, Peninsula drug company smells success, $100 million payoffMay 15, 2025 | bizjournals.comCytomX Therapeutics (NASDAQ:CTMX) Given "Outperform" Rating at WedbushWedbush reissued an "outperform" rating and issued a $6.00 target price (up from $5.00) on shares of CytomX Therapeutics in a report on Monday.May 14, 2025 | marketbeat.comCytomX Therapeutics Sees Unusually Large Options Volume (NASDAQ:CTMX)CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) was the recipient of some unusual options trading on Monday. Traders purchased 4,235 call options on the stock. This represents an increase of approximately 2,705% compared to the average volume of 151 call options.May 14, 2025 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Announces Quarterly Earnings ResultsCytomX Therapeutics (NASDAQ:CTMX - Get Free Report) issued its quarterly earnings results on Monday. The biotechnology company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.17. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same quarter in the previous year, the company posted $0.17 earnings per share.May 14, 2025 | marketbeat.comCytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish?May 14, 2025 | seekingalpha.comCytomX Stock Hits 2-Month High After Upbeat Q1 Earnings, Promising Early Data For Cancer DrugMay 13, 2025 | msn.comCytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)May 12, 2025 | seekingalpha.comCytomX Therapeutics shares soar on positive cancer drug dataMay 12, 2025 | investing.comNano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data ReportMay 12, 2025 | benzinga.comCytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common StockMay 12, 2025 | globenewswire.comCytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comCytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)May 12, 2025 | globenewswire.comExploring CytomX Therapeutics's Earnings ExpectationsMay 9, 2025 | benzinga.comCytomX Therapeutics Inc (CTMX) Q1 2025 Earnings Report Preview: What to Look ForMay 9, 2025 | finance.yahoo.comCytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on WednesdayCytomX Therapeutics (NASDAQ:CTMX) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-cytomx-therapeutics-inc-stock/)May 9, 2025 | marketbeat.comCytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025May 5, 2025 | globenewswire.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Acquired by JPMorgan Chase & Co.JPMorgan Chase & Co. increased its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 288,736.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 811,630 shares of the biotechnology compApril 30, 2025 | marketbeat.comCorcept Therapeutics to Report Q1 Earnings: What's in the Cards?April 29, 2025 | msn.comCytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual MeetingApril 28, 2025 | globenewswire.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and three have given a buy rating toApril 26, 2025 | marketbeat.comBeam Therapeutics to Report Q1 Earnings: What's in the Cards?April 25, 2025 | msn.comAmicus Therapeutics to Report Q1 Earnings: What's in the Cards?April 23, 2025 | msn.comAltium Capital Management LLC Trims Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX)Altium Capital Management LLC decreased its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 48.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 467,491 shares of the biotechnology compaApril 20, 2025 | marketbeat.comPiper Sandler Reaffirms Their Buy Rating on CytomX Therapeutics (CTMX)April 15, 2025 | markets.businessinsider.comCytomX Therapeutics assumed with an Overweight at Piper SandlerApril 15, 2025 | markets.businessinsider.comCytomX Therapeutics participates in a conference call with JPMorganApril 2, 2025 | markets.businessinsider.comStockNews.com Downgrades CytomX Therapeutics (NASDAQ:CTMX) to HoldStockNews.com cut CytomX Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday.April 1, 2025 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Up 91.5% in MarchCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 9,000,000 shares, an increase of 91.5% from the February 28th total of 4,700,000 shares. Approximately 12.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,790,000 shares, the short-interest ratio is presently 5.0 days.March 29, 2025 | marketbeat.comInsider Selling: CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Sells 19,512 Shares of StockCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) SVP Marcia Belvin sold 19,512 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $0.60, for a total transaction of $11,707.20. Following the completion of the sale, the senior vice president now directly owns 248,636 shares in the company, valued at $149,181.60. This trade represents a 7.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.March 21, 2025 | marketbeat.comSean A. Mccarthy Sells 37,656 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) StockCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) CEO Sean A. Mccarthy sold 37,656 shares of CytomX Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $0.60, for a total value of $22,593.60. Following the sale, the chief executive officer now owns 995,195 shares in the company, valued at $597,117. This represents a 3.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 21, 2025 | marketbeat.comInsider Selling: CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Sells 19,512 Shares of StockMarch 21, 2025 | insidertrades.comCytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal yearMarch 14, 2025 | uk.investing.comCytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by StockNews.comStockNews.com raised shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a research report on Monday.March 11, 2025 | marketbeat.com Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address CTMX Media Mentions By Week CTMX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTMX News Sentiment▼1.540.67▲Average Medical News Sentiment CTMX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTMX Articles This Week▼12▲CTMX Articles Average Week Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Pharming Group News Today Replimune Group News Today Gyre Therapeutics News Today Cronos Group News Today Trevi Therapeutics News Today Phathom Pharmaceuticals News Today Immatics News Today Anavex Life Sciences News Today Vir Biotechnology News Today AnaptysBio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTMX) was last updated on 6/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTMX Stock Free CTMX Stock Alerts